For the relief of symptoms of colds and influenza, including the relief of aches and pains, sore throat, headache, nasal congestion, lowering of temperature and chesty coughs.
Horizon Therapeutics plc announced that the FDA has accepted Horizon's New Drug Application (NDA) for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral...
This product relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. It is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. This product is indicated in pregnant and lactating women making a quit attempt.
Horizon Therapeutics plc announced that the FDA has approved Procysbi (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis.